Proof of Principle Study to Evaluate the Safety, PK, Viral Shedding and Efficacy of Pentarlandir™ UPPTA for Patients With Early COVID-19
NCT ID: NCT04911777
Last Updated: 2021-12-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
90 participants
INTERVENTIONAL
2021-08-24
2022-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Upon signing informed consent and evaluating medical history, concomitant medications, oxygen saturation (SaO2) at room air and vital signs, a focused physical examination of the heart and lungs will be performed. Subjects will be randomized into High-Dose, Low-Dose, and Placebo group in a 1:1:1 ratio at the final sample, but the enrollment will be staggered. In the first phase, 45 study subjects will be randomized at 2:1 ratio to Pentarlandir™ UPPTA low dose or placebo. After all the forty-five (45) subjects have completed the Day 21 assessment or early terminated (14-day dosing and 7 days of followed-up), DSMB will review the safety from the cohort and provide concurrence with proceeding with the higher dose cohort. If DSMB deems that the study is safe to proceed, another 45 subjects will be randomized at 2:1 ratio to Pentarlandir™ UPPTA high dose or placebo in the second phase. Both staggered cohorts will have the same stopping rules.
During both phases of study, specimens for quantification of the viral genome, inflammatory markers, and safety laboratory tests will be collected. The IP will be dispensed to the study subjects and the subject will take the first dose of the study treatment at the clinic. Study subjects will be instructed (and provided) to use a device for ePRO for how to complete the patient-reported diary.
The subjects will take the IP orally. Subjects in the low-dose group will take from each bottle of the active drug and placebo every 8 hours (q8h); for the high-dose group, from each of the two bottles of active drug; and for the placebo group, from each of the two bottles of placebo for 14 days. The first treatment dose should be taken within 4 days of COVID-19 diagnosis. Physical examination, specimen collection, laboratory evaluations and urine pregnancy test, vital signs, pulse oxygen saturation and clinical symptom and status determination will be conducted.
Subjects who meet the eligibility criteria will be randomized. All subjects who fail to meet eligibility criteria are considered screen failures and are exited from the study without further evaluation.
Screening and Randomization (V1, Day 1):
After determining the eligibility, the study subjects will be randomized 2:1 to Pentarlandir™ UPPTA (either low or high dose) or placebo. The IP for treatment period will be dispensed to the study subjects and the subject will take the first dose of the study treatment at the study site. Study subjects will be instructed (and provided) how to complete the electronic patient reported outcome (ePRO) on a device.
Treatment Period (V2 - V14 (EOT), Day 2 - Day 14):
The subjects will continue to document the daily diary of ePRO. Total 13 visits are included in this period. Except 4 in-persons visits (V3, V7, V10, and V14), no in-person visit is expected during the study. Subjects will return to the clinical study sites to collect specimens for quantification of viral genome, inflammatory markers, pharmacokinetic and safety laboratory tests as well as record the SaO2, oral temperature, heart and respiratory rate, blood pressure, symptoms and concomitant medications, to document clinical status and adverse events (AEs), and IP accountability will be monitored. In addition, clinical symptom assessments and 7-category ordinal scale will be evaluated as well along with safety laboratory evaluations to determine whether the subject will continue to take the IP or stop the clinical trial. The subject will return the study treatment bottles at EOT visit.
Except for the in-person visits, subjects will be phone-called once every day between 8:00 AM and 7:00 PM on the visits to record concomitant medications and to document clinical status and 7-category ordinal scale as well as adverse events (AEs) to determine whether the subject will be taken of the IP and/or stop the clinical trial.
Weekly Follow-Up Period (V15 - V20, Day 15 - Day 56):
Between Day 15 to 28, subjects will perform the ePRO diary daily. In addition to ePRO, study subjects will be called every 7±2 days after EOT visit to document final outcome and AEs up to Day 56. AE/SAEs, hospital and ICU lengths of stays, and mortality in hospitalized subjects will be documented.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pentarlandir™ UPPTA - High Dose
High dose of Pentarlandir™ UPPTA, q8h (over 3 hours postprandially)
Pentarlandir™ UPPTA
Pentarlandir™ UPPTA is a white oral capsule (with 188 mg of UPPTA)
Pentarlandir™ UPPTA - Low Dose
Low dose of Pentarlandir™ UPPTA and placebo, q8h (over 3 hours postprandially)
Pentarlandir™ UPPTA
Pentarlandir™ UPPTA is a white oral capsule (with 188 mg of UPPTA)
Placebo
The placebo of Pentarlandir™ UPPTA is a white oral capsule (without UPPTA)
Placebo
Pacebo, q8h (over 3 hours postprandially)
Placebo
The placebo of Pentarlandir™ UPPTA is a white oral capsule (without UPPTA)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pentarlandir™ UPPTA
Pentarlandir™ UPPTA is a white oral capsule (with 188 mg of UPPTA)
Placebo
The placebo of Pentarlandir™ UPPTA is a white oral capsule (without UPPTA)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Able and willing to provide informed consent.
3. Able and willing to sufficiently operate smart phones and study-provided monitoring devices per the Investigator.
4. Early COVID-19 diagnosis with mild severity defined as meeting all of the below:
1. Confirmation of COVID-19 by a PCR-based diagnostic within 4 days of randomization.
* COVID-19 with mild symptoms, defined as a score of 8 or higher on the clinical symptom score.
* Clinical symptom score includes 9 items in fever or chills, myalgia, cough, headache, sore throat, new loss of test or smell, gastrointestinal symptoms (nausea, vomiting, diarrhea or abdominal pain), congestion or running nose, and fatigue (malaise) as assessed and recorded by the investigator.
Note: The total score per patient ranges from 0 to 27 points. Each symptom is rated from 0 to 3. \[0 = none, 1 = mild, 2 = moderate, and 3 = severe\]
2. No signs of a more serious lower airway disease per clinical exam, chest X-ray or chest CT.
3. Resting RR ≤ 20, HR ≤ 90, oxygen saturation (pulse oximetry) ≥ 95% on room air.
5. For women of childbearing potential (women who are not permanently sterile \[documented hysterectomy, bilateral tubal ligation, salpingectomy, or oophorectomy\] or postmenopausal \[12 months with no menses without an alternative medical cause\]):
1. Negative urine pregnancy test at screening.
2. Willingness to practice a highly effective method of contraception that includes, but is not limited to, abstinence, sex only with persons of the same sex, monogamous relationship with a postmenopausal partner, monogamous relationship with vasectomize partner, vasectomy, licensed hormonal methods, intrauterine device, or consistent use of a barrier method (e.g., condom, diaphragm) with spermicide for 28 days after the last dose of study medication.
6. Ability and willingness to comply with all aspects of the study through the entire study period.
Exclusion Criteria
2. Pregnant or lactating women.
3. Patients with shortness of breath at rest.
4. Findings on physical examination or available imaging studies suggesting rapid disease progression of COVID-19.
5. Signs or symptoms indicative of pneumonia or any other lower respiratory tract disorders, or clinically significant findings in available lung imaging studies suggestive of such disorders.
6. Need for immediate hospitalization, oxygen supplementation or mechanical ventilation.
7. Obstructive airway diseases, including chronic obstructive pulmonary disease (COPD) and asthma, or other respiratory disease that could exacerbate independent of COVID-19.
8. Use of remdesivir, chloroquine, hydroxychloroquine, convalescent plasma, other monoclonal antibody therapies, include REGEN-COV (casirivimab and imdevimab), bamlanivimab (plus etesevimab), dexamethasone, ivermectin, baricitinib, and other Janus kinase inhibitors, Bruton's tyrosine kinase inhibitors, tocilizumab (and other interleukin-6 inhibitors) and any other therapy with EUA or approval and other investigational agents for COVID-19.
9. Patients who are participating in other clinical trials.
10. History of conditions associated with immunocompromise, or treatments known to affect the immune system, including but not limited to oral or intravenous corticosteroids, alkylating drugs, antimetabolites, cytotoxic drugs, other chemotherapy, radiation, immune-modulating biologics, within 30 days of screening.
11. Barium enemas within the last 30 days.
12. Taking OTC or prescribed medicine which has compound as active ingredient.
13. Any unstable or uncontrolled medical illnesses such as neurological disorders, cardiovascular disorders, diabetes, hepatic or renal disorders that per the Investigator would intervene with the study conduct or study results interpretation.
14. Any other medical, psychiatric, or social condition or occupational or other responsibility that in the judgment of the Investigator would interfere with or serve as a contraindication to protocol adherence, assessment of safety, or a patient's ability to give informed consent or respond to the study procedures or questions during the personal visits or the video calls.
15. High-risk individuals are those who meet at least one of the following criteria:
1. Aged ≥ 65 years
2. Body mass index (BMI) \> 30
3. Pregnancy
4. Chronic kidney disease
5. Diabetes
6. Immunosuppressive disease or immunosuppressive treatment
7. Cardiovascular disease (including congenital heart disease) or hypertension
8. Chronic lung diseases (for example, chronic obstructive pulmonary disease, asthma \[moderate-to-severe\], interstitial lung disease, cystic fibrosis and pulmonary hypertension)
9. Sickle cell disease
10. Neurodevelopmental disorders (for example, cerebral palsy) or other conditions that confer medical complexity (for example, genetic or metabolic syndromes and severe congenital anomalies)
11. Having a medical-related technological dependence (for example, tracheostomy, gastrostomy, or positive pressure ventilation \[not related to COVID-19\]
12. Exclusion is not limited to the medical conditions or factors listed above. The investigators have to consider the benefit-risk for an individual patient to determine other medical conditions or factors (for example, overweight, race or ethnicity) may also place individual patients at high risk for progression to severe COVID-19 and be excluded.
18 Years
64 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
SyneuRx International (Taiwan) Corp
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cullman Clinical Trials
Cullman, Alabama, United States
Cactus Clinical Research, Inc.
Gilbert, Arizona, United States
Synergy Healthcare
Bradenton, Florida, United States
Columbus Clinical Services
Miami, Florida, United States
C'A Research, LLC
Miami, Florida, United States
CTMD Research
Palm Springs, Florida, United States
Eminat Research Group
Plantation, Florida, United States
Elite Medical Research
Dallas, Texas, United States
Diversified Medical Practices
Houston, Texas, United States
Accurate Clinical Research
Houston, Texas, United States
1960 Family Practice
Houston, Texas, United States
Ayinde Clinical Research
Irving, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Cheryl Hargrove
Role: primary
Jana Swindle
Role: backup
Regina Almaraz
Role: primary
Linda Mora
Role: primary
Sara Llerena
Role: primary
Bertha Cano
Role: backup
Mario Llobet
Role: primary
Doris Rodriguez
Role: primary
Martha Alcantara
Role: backup
Hanney Musa
Role: primary
Kaothar Hashim
Role: backup
Denise Rodriguez
Role: primary
Ana Batista
Role: primary
Adianez Diaz
Role: backup
Alice Mouton
Role: primary
Gambo Dangwaran
Role: backup
Udeme Ebong
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SNR08-Covid19
Identifier Type: -
Identifier Source: org_study_id